UPDATE: Amgen Announces Phase 3 ASPIRE Trial of Kyprolis Met Primary Endpoint, Helped Patients Live Longer without Worsening

Amgen (NASDAQ: AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that ...